Compare BB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BB | MESO |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | Canada | Australia |
| Employees | N/A | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1999 | N/A |
| Metric | BB | MESO |
|---|---|---|
| Price | $3.44 | $15.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.12 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 270.6K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.91 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $534,900,000.00 | N/A |
| Revenue This Year | $4.19 | $633.98 |
| Revenue Next Year | $7.63 | $29.51 |
| P/E Ratio | $70.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.80 | $9.61 |
| 52 Week High | $5.32 | $21.50 |
| Indicator | BB | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 44.07 |
| Support Level | $3.34 | $15.62 |
| Resistance Level | $3.59 | $16.32 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 53.09 | 61.03 |
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.